Exosomal miR‑34b inhibits proliferation and the epithelial‑mesenchymal transition by targeting Notch2 in ovarian cancer
- Shenglian Lu
- Wuxia Liu
- Hong Shi
- Han Zhou
Affiliations: Department of Obstetrics and Gynecology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China, Department of Special Clinic, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China, Department of Ultrasound, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China, Center for Reproductive Medicine, The Second People's Hospital of Changzhou, Changzhou, Jiangsu 213003, P.R. China
- Published online on: July 9, 2020 https://doi.org/10.3892/ol.2020.11837
Copyright: © Lu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Exosomal microRNA (miR) can affect signaling pathways in various physiological and pathological conditions, including ovarian cancer (OC). miR‑34b, the first microRNA targeted in a human clinical trial for cancer treatment, exhibited decreased expression in several cancer types. However, the biological function of exosomal miR‑34b in OC has not been elucidated. In the present study, using reverse transcription‑quantitative PCR, it was reported that exosomal miR‑34b is downregulated in OC cells. Exosomal miR‑34b reduced cell proliferation and epithelial‑mesenchymal transition (EMT) in the OC cell line SKOV3. In addition, it was confirmed that Notch2, which is upregulated in SKOV3 cells, is a target of miR‑34b. Moreover, exosomal miR‑34b and Notch2 levels were found to be negatively correlated. The present data highlights the importance of exosomal miR‑34b‑mediated inhibition of cell proliferation and EMT, suggesting that exosomal miR‑34b has value as a diagnostic biomarker and a potential molecular target for the treatment of OC.